What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Another Take on the 2022 EULAR RA Treatment Guidelines
Dr. Peter Nash reviews the new 2022 EULAR RA Treatment Guidelines, presented at #EULAR2022.
Watch video →
EULAR 2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
Watch video →
2022 ASAS/EULAR Recommendations on the Management of Axial Spondyloarthritis
Dr. Peter Nash discusses the new ASAS/EULAR Spondyloarthritis treatment guidelines presented at EULAR 2022
Watch video →
RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
Dr. Jonathan Kay reports on RA-related sessions and abstracts from day 1 at EULAR 2022.
Watch video →
New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force.
Watch video →
EULAR 2022 - Day 1 Faculty Recap Panel
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at EULAR 2022 - Guidelines, Lupus, and more.
Watch video →
Dr. John Cush RheumNow
3 years 2 months ago
ALL-HEART study presented in Barcelona at ESC Congress 2022 showed that allopurinol given to 5,721 older adults without gout, failed to reduce # nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in ischaemic heart Dz pts https://t.co/I0dFXQa6Ao https://t.co/8IevQ4uwUY
Dr. John Cush RheumNow
3 years 2 months ago
Bidirectional Association Between Depression and Rheumatoid Arthritis
A recent meta-analysis suggests a bidirectional association between RA and depression. Finding RA patients with depression yields an 80% increased mortality risk.
https://t.co/NUyZ2jAWzE
Dr. John Cush RheumNow
3 years 2 months ago
Weight Loss Slows Knee OA Progression
Declines in body mass index (BMI) were linked with slower worsening of knee osteoarthritis (OA), according to data from three large longitudinal cohort studies.
https://t.co/jJlSTdBdXT https://t.co/9mPJiVT9nE
Dr. John Cush RheumNow
3 years 2 months ago
Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.
https://t.co/8bAoqp79Mg https://t.co/K2Z1LwPTiS
Dr. John Cush RheumNow
3 years 2 months ago
Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/VKciXY0klN https://t.co/LdMu3RrlZK
Donald Thomas, MD lupuscyclopedia
3 years 2 months ago
Learn how to manage lupus: 'The Lupus Encyclopedia: A Comprehensive Guide for Patients and Families' - on #BookBuzz - https://t.co/hvnoFRiabA
Leonard Calabrese LCalabreseDO
3 years 2 months ago
h/t @alhkim concluded. “Get Evusheld into your patients" - We add give aggressive out pt mgmnt for #Breakthrough
@CCalabreseDO
@philipcrobinson @drdavidliew
B-cell depleting therapies ‘biggest threat’ for reduced SARS-CoV-2 mRNA vaccine response https://t.co/VZRwg0Q6cw
Dr. John Cush RheumNow
3 years 2 months ago
Hyaluronic Acid Knee Injections Equivalent to Placebo
In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.
https://t.co/NwJkyECfgM https://t.co/qGLQMWjQG4
Dr. John Cush RheumNow
3 years 2 months ago
Charcot (neuropathic) arthropathy of elbow due to Syringomyelia - review of 50 pts. Median age 45 yrs, 2/3 isolated elbow arthritis; other joints: shoulder > wrist > MCPs/IPs. 2/3 had Chiari malformations, sensory/motor deficits, or ulnar neuropathy https://t.co/2hEArpbL8p https://t.co/MK4VTzSSRB
Dr. John Cush RheumNow
3 years 2 months ago
Review of VTE risk with JAK inhibitors
- Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY
- Baricitinib: IR of DVT/PE was 0.5/100PY
- Filgotinib: 200mg VTEs 0.2/100PY
Most VTE occured in LT extension of RCT https://t.co/xvf0kQUMel https://t.co/Bj6fmkktP7
Dr. John Cush RheumNow
3 years 2 months ago
Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.
Are you a fan of our podcast? Please rate, like and review us wherever you get your podcast.
https://t.co/uj6QF3EqlU https://t.co/lFpoRfkEqU
Dr. John Cush RheumNow
3 years 2 months ago
Melatonin Use Growing, Inappropriate & Potentially Unsafe
With nearly 1/3 of adults, adolescents and children having sleep difficulties, many resort to using melatonin. But is it effective, safe and warranted?
https://t.co/8TA76yAbwr https://t.co/ADYklo0yMz
Dr. John Cush RheumNow
3 years 2 months ago
Olokizumab, another IL-6 Inhibitor for RA
This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets interleukin-6 (IL-6) in patients with rheumatoid arthritis (RA).
https://t.co/VMz8xzffiZ https://t.co/eaA4CUWvrv
Dr. John Cush RheumNow
3 years 2 months ago
Hyaluronic Acid Knee Injections Equivalent to Placebo
In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.
https://t.co/1pSVr3VI4t https://t.co/DvFN7WQdTp
The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.
Poster Hall